Table 3. Efficacy data according to RECIST v1.1.
| Groups | CR | PR | SD | PD | ORR (%) | DCR (%) | P (for ORR) |
|---|---|---|---|---|---|---|---|
| Total | 2 | 13 | 31 | 11 | 26.3 | 80.7 | |
| Sarcoma type | 0.0031 | ||||||
| L-sarcoma | 1 | 4 | 25 | 8 | 13.2 | 78.9 | |
| Non-L-sarcoma | 1 | 9 | 6 | 3 | 52.6 | 84.2 | |
| FNCLCC grade | 0.0486 | ||||||
| G1 | 0 | 0 | 10 | 1 | 0.0 | 90.9 | |
| G2 | 2 | 5 | 11 | 3 | 33.3 | 85.7 | |
| G3 | 0 | 8 | 10 | 4 | 36.4 | 81.9 |
RECIST, response evaluation criteria in solid tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; FNCLCC, Fédération Nationale des Centres de Lutte Contre le Cancer.